Current Progress in the Development of mRNA Vaccines Against Bacterial Infections

Int J Mol Sci. 2024 Dec 6;25(23):13139. doi: 10.3390/ijms252313139.

Abstract

Bacterial infections have accompanied humanity for centuries. The discovery of the first antibiotics and the subsequent golden era of their discovery temporarily shifted the balance in this confrontation to the side of humans. Nevertheless, the excessive and improper use of antibacterial drugs and the evolution of bacteria has gotten the better of humans again. Therefore, today, the search for new antibacterial drugs or the development of alternative approaches to the prevention and treatment of bacterial infections is relevant and topical again. Vaccination is one of the most effective strategies for the prevention of bacterial infections. The success of new-generation vaccines, such as mRNA vaccines, in the fight against viral infections has prompted many researchers to design mRNA vaccines against bacterial infections. Nevertheless, the biology of bacteria and their interactions with the host's immunity are much more complex compared to viruses. In this review, we discuss structural features and key mechanisms of evasion of an immune response for nine species of bacterial pathogens against which mRNA vaccines have been developed and tested in animals. We focus on the results of experiments involving the application of mRNA vaccines against various bacterial pathogens in animal models and discuss possible options for improving the vaccines' effectiveness. This is one of the first comprehensive reviews of the use of mRNA vaccines against bacterial infections in vivo to improve our knowledge.

Keywords: B. burgdorferi; L. monocytogenes; M. tuberculosis; P. aeruginosa; RNA vaccine; S. pyogenes; bacterial infection.

Publication types

  • Review

MeSH terms

  • Animals
  • Bacteria / genetics
  • Bacteria / immunology
  • Bacterial Infections* / immunology
  • Bacterial Infections* / prevention & control
  • Bacterial Vaccines* / genetics
  • Bacterial Vaccines* / immunology
  • Humans
  • RNA, Messenger / genetics
  • RNA, Messenger / immunology
  • Vaccine Development*
  • Vaccines, Synthetic / immunology
  • mRNA Vaccines* / genetics
  • mRNA Vaccines* / immunology

Substances

  • Bacterial Vaccines
  • mRNA Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic

Grants and funding

This work was supported by the Ministry of Science and Higher Education of the Russian Federation (agreement no. 075-10-2021-113, unique project ID RF—193021 × 0001).